Patents by Inventor Stephen E. Mercer

Stephen E. Mercer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Constrained compounds as CGRP-receptor antagonists
    Patent number: 7384931
    Abstract: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: June 10, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Stephen E. Mercer, Haiquan Fang
  • Constrained compounds as CGRP-receptor antagonists
    Patent number: 7384930
    Abstract: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: June 10, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Stephen E. Mercer, Haiquan Fang
  • CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
    Publication number: 20070259851
    Abstract: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Application
    Filed: May 1, 2007
    Publication date: November 8, 2007
    Inventors: Prasad V. Chaturvedula, Stephen E. Mercer, Haiquan Fang, Xiaojun Han, Guanglin Luo, Gene M. Dubowchik, Graham S. Poindexter
  • CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
    Publication number: 20070259850
    Abstract: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Application
    Filed: May 1, 2007
    Publication date: November 8, 2007
    Inventors: Stephen E. Mercer, Prasad V. Chaturvedula
  • Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-? converting enzyme
    Patent number: 7125870
    Abstract: The present application describes novel isoxazoline of formula I or II: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, R1, R2, R3, R4, Z, U, X, Y, Za, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-? converting enzyme (TACE), or a combination thereof.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: October 24, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chu-Biao Xue, Thomas P. Maduskuie, Stephen E. Mercer
  • Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme
    Publication number: 20040122005
    Abstract: The present application describes novel isoxazoline of formula I or II: 1
    Type: Application
    Filed: October 30, 2003
    Publication date: June 24, 2004
    Inventors: Chu-Biao Xue, Thomas P. Maduskuie, Stephen E. Mercer
  • Lactam metalloprotease inhibitors
    Patent number: 6620823
    Abstract: The present application describes novel lactams and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 4-8 membered cyclic amide comprising 0-3 additional heteroatoms selected from N, O, and S, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: September 16, 2003
    Assignee: Bristol-Myers Squibb Pharme Company
    Inventors: Thomas P Maduskuie, Jingwu Duan, Stephen E Mercer
  • Novel lactam metalloprotease inhibitors
    Publication number: 20020042398
    Abstract: The present application describes novel lactams and derivatives thereof of formula I: 1
    Type: Application
    Filed: July 10, 2001
    Publication date: April 11, 2002
    Inventors: Thomas P. Maduskuie, Jingwu Duan, Stephen E. Mercer